Omalizumab for chronic urticaria in Latin America
Open Access
- 1 January 2016
- journal article
- Published by Elsevier BV in World Allergy Organization Journal
- Vol. 9 (1), 36
- https://doi.org/10.1186/s40413-016-0127-y
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- An algorithm for treating chronic urticaria with omalizumab: Dose interval should be individualizedJournal of Allergy and Clinical Immunology, 2013
- Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practiceExpert Opinion on Biological Therapy, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaThe New England Journal of Medicine, 2013
- A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticariaJournal of Allergy and Clinical Immunology, 2011
- Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidaseJournal of Allergy and Clinical Immunology, 2011
- Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1Allergy, 2010
- Maintenance of Remission With Low-Dose Omalizumab in Long-Lasting, Refractory Chronic UrticariaAnnals of Allergy, Asthma & Immunology, 2010
- How to assess disease activity in patients with chronic urticaria?Allergy, 2008
- Annual Direct and Indirect Health Care Costs of Chronic Idiopathic UrticariaArchives of Dermatology, 2008
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994